WESTON, Fla.--(BUSINESS WIRE)--Nov. 30, 2005--Apotex Corp. today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for ofloxacin otic, 0.3%. Apotex confirmed it was first-to-file and that it will receive 180-days of market exclusivity. Shipments of the drug are expected to commence pending the successful outcome of ongoing litigation.
